The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
May. 15, 2018
Filed:
Sep. 01, 2016
Applicant:
Turun Yliopisto, Turun yliopisto, FI;
Inventors:
Jukka Westermarck, Turku, FI;
Anna Cvrljevic, Lemu, FI;
Assignee:
TURUN YLIOPISTO, Turku, FI;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07H 21/02 (2006.01); A61K 31/713 (2006.01); A61K 31/436 (2006.01); A61K 31/337 (2006.01); A61K 31/404 (2006.01); A61K 31/4188 (2006.01); A61K 31/517 (2006.01); A61K 31/553 (2006.01); A61K 45/06 (2006.01); A61K 31/15 (2006.01); A61K 31/4545 (2006.01); A61K 31/5377 (2006.01); A61K 31/7068 (2006.01); A61K 33/24 (2006.01); A61K 38/00 (2006.01); A61K 31/00 (2006.01); A61K 31/09 (2006.01); A61K 31/165 (2006.01); A61K 31/166 (2006.01); A61K 31/245 (2006.01); A61K 31/282 (2006.01); A61K 31/407 (2006.01); A61K 31/4184 (2006.01); A61K 31/4406 (2006.01); A61K 31/444 (2006.01); A61K 31/4725 (2006.01); A61K 31/497 (2006.01); A61K 31/498 (2006.01); A61K 31/506 (2006.01); A61K 31/513 (2006.01); A61K 31/519 (2006.01); A61K 31/5375 (2006.01); A61K 31/55 (2006.01); A61K 31/551 (2006.01); A61K 31/7105 (2006.01); A61K 31/7088 (2006.01); C12N 15/113 (2010.01); C12Q 1/68 (2018.01); G01N 33/574 (2006.01); A61K 31/502 (2006.01);
U.S. Cl.
CPC ...
A61K 31/713 (2013.01); A61K 31/00 (2013.01); A61K 31/09 (2013.01); A61K 31/15 (2013.01); A61K 31/165 (2013.01); A61K 31/166 (2013.01); A61K 31/245 (2013.01); A61K 31/282 (2013.01); A61K 31/337 (2013.01); A61K 31/404 (2013.01); A61K 31/407 (2013.01); A61K 31/4184 (2013.01); A61K 31/4188 (2013.01); A61K 31/436 (2013.01); A61K 31/444 (2013.01); A61K 31/4406 (2013.01); A61K 31/4545 (2013.01); A61K 31/4725 (2013.01); A61K 31/497 (2013.01); A61K 31/498 (2013.01); A61K 31/502 (2013.01); A61K 31/506 (2013.01); A61K 31/513 (2013.01); A61K 31/517 (2013.01); A61K 31/519 (2013.01); A61K 31/5375 (2013.01); A61K 31/5377 (2013.01); A61K 31/55 (2013.01); A61K 31/551 (2013.01); A61K 31/553 (2013.01); A61K 31/7068 (2013.01); A61K 31/7088 (2013.01); A61K 31/7105 (2013.01); A61K 33/24 (2013.01); A61K 38/00 (2013.01); A61K 45/06 (2013.01); C12N 15/113 (2013.01); C12Q 1/6886 (2013.01); G01N 33/57496 (2013.01); C12N 2310/14 (2013.01); C12N 2320/30 (2013.01); C12Q 2600/106 (2013.01); C12Q 2600/158 (2013.01); G01N 2333/4704 (2013.01); G01N 2333/4748 (2013.01);
Abstract
The invention is based on a finding that silencing CIP2A (KIAA1524) gene sensitizes cancer cells for apoptosis-inducing activity of certain small molecule chemotherapeutic agents. Thus, the invention is directed to a respective combination therapy, sensitization method and pharmaceutical compositions. The invention further relates to a method of selecting cancer therapy for a subject on the basis of CIP2A and p53 expression and/or protein activity in a sample obtained from said subject.